Literature DB >> 9121147

Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma.

J D Wagner1, D Schauwecker, G Hutchins, J J Coleman.   

Abstract

BACKGROUND: The purpose of this pilot study is to determine the feasibility of positron emission tomography with fluorodeoxyglucose (FDG-PET) for detection of nonpalpable regional lymph node metastases in patients with melanoma.
METHODS: Adult patients with histologically proven cutaneous melanoma planned to undergo surgical lymphadenectomy for treatment of nonpalpable subclinical or residual metastatic melanoma in regional lymph node basin(s) participated. Each patient underwent attenuation-corrected PET imaging of the regional lymph node basin(s) with F18 fluorodeoxyglucose (FDG) followed by complete surgical lymphadenectomy. FDG-PET scans were interpreted prospectively by an experienced nuclear medicine physician. FDG-PET scan interpretations and histologic results were then correlated.
RESULTS: Eleven patients underwent 12 FDG-PET scans followed by 12 operations to clear 14 regional lymph node basins. FDG-PET correctly predicted the presence of metastatic melanoma in seven of seven surgical specimens. FDG-PET scans correctly predicted the absence of disease in seven of seven histologically negative node basins. Sensitivity was 1.0; specificity was 1.0.
CONCLUSIONS: This study suggests that increased fluorodeoxyglucose uptake in palpably unremarkable regional lymph node basins in patients with melanoma is highly suggestive of metastatic disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9121147     DOI: 10.1002/(sici)1096-9098(199703)64:3<181::aid-jso2>3.0.co;2-6

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  Effectiveness of positron emission tomography for the detection of melanoma metastases.

Authors:  W D Holder; R L White; J H Zuger; E J Easton; F L Greene
Journal:  Ann Surg       Date:  1998-05       Impact factor: 12.969

2.  How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning: the case of lymph node staging in melanoma.

Authors:  G S Mijnhout; O S Hoekstra; A van Lingen; P J van Diest; H J Adèr; A A Lammertsma; R Pijpers; S Meijer; G J J Teule
Journal:  J Clin Pathol       Date:  2003-04       Impact factor: 3.411

3.  A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.

Authors:  Georgia M Beasley; Colin Parsons; Gloria Broadwater; M Angelica Selim; Suroosh Marzban; Amy P Abernethy; April K S Salama; Edward A Eikman; Terence Wong; Jonathan S Zager; Douglas S Tyler
Journal:  Ann Surg       Date:  2012-08       Impact factor: 12.969

4.  Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.

Authors:  Jacqueline Dinnes; Lavinia Ferrante di Ruffano; Yemisi Takwoingi; Seau Tak Cheung; Paul Nathan; Rubeta N Matin; Naomi Chuchu; Sue Ann Chan; Alana Durack; Susan E Bayliss; Abha Gulati; Lopa Patel; Clare Davenport; Kathie Godfrey; Manil Subesinghe; Zoe Traill; Jonathan J Deeks; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-07-01

5.  Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma.

Authors:  Felisa Jiménez-Requena; Roberto C Delgado-Bolton; Cristina Fernández-Pérez; Sanjiv S Gambhir; Judy Schwimmer; José M Pérez-Vázquez; José L Carreras-Delgado
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-02       Impact factor: 9.236

Review 6.  Visualizing cancer and immune cell function with metabolic positron emission tomography.

Authors:  Rachel E Laing; Evan Nair-Gill; Owen N Witte; Caius G Radu
Journal:  Curr Opin Genet Dev       Date:  2010-02       Impact factor: 5.578

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.